Personnel changes at Alchemia

25-Feb-2014 - Australia

Alchemia Limited announced the appointment of Thomas Liquard as Chief Executive Officer following the departure of Charles Walker. Mr Liquard, who joined Alchemia in December 2013 as Chief Operating Officer, brings significant commercial and managerial expertise to the company having most recently served as Senior Director, Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer, Inc. in New York.

“The company has been diligently preparing for its transformation into a broader commercial organization and with our pivotal Phase 3 trial data read-out on the horizon for HA-irinotecan, along with a developing oncology pipeline, we are delighted to make this CEO appointment,” stated Santo J. Costa, Alchemia’s Incoming Chairman. “Thomas’ impressive background and strategic mindset makes him extremely qualified to lead Alchemia through this next stage of corporate growth. On behalf of the Board, I wish to thank Charlie for his service over the last year in helping guide our transition to products beyond fondaparinux.”

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance